Illumina Innovation Fund II GP, L.L.C. bought ALMR
April 20, 2026 · Form 4 insider transaction
Illumina Innovation Fund II GP, L.L.C. bought 922,152 shares of Alamar Biosciences, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.
Footnotes
The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO.; The securities are held by Illumina Innovation Fund II, L.P. ("IIF II"). Illumina Innovation Fund II GP, L.L.C. ("IIF II GP") is the general partner of IIF II. Nicholas Naclerio ("Mr. Naclerio"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any.